Showing 1 - 10 of 29,941
The problems of the uninsured, cost escalation, and improving quality in United States health care are once again on the front pages. There is a sense that these problems can be resolved despite the magnitude of the issues. This optimism is related to new techniques and approaches to governance....
Persistent link: https://www.econbiz.de/10014060798
The book Patent Remedies and Complex Products: Toward a Global Consensus presents a laudable effort to examine the … underpinnings of patent remedies and how these remedies should be applied in our world of ever more advanced multi … perspective of U.S. patent and antitrust litigation. More specifically, this Comment focuses on several critical aspects of the …
Persistent link: https://www.econbiz.de/10012825111
Persistent link: https://www.econbiz.de/10001753201
Persistent link: https://www.econbiz.de/10012433661
New medical technologies are a leading driver of U.S. health care spending. This report identifies promising policy options to change which medical technologies are created, with two related policy goals: (1) Reduce total health care spending with the smallest possible loss of health benefits,...
Persistent link: https://www.econbiz.de/10010424486
a patent system would function with the proposed changes. A chart, keyed to the draft treaty articles, is included to … basic international patent law, it is written for general patent specialists and business persons who want to know what is … going on at the patent harmonization meetings. Section III is a detailed review of the 7th meeting discussions, based on …
Persistent link: https://www.econbiz.de/10014192646
specialist circles of patent law, Hatch-Waxman Amendment ANDAs, for which final FDA approval is attained, can create patent …-related rights, that provide a shorter route to market entry for generic pharmaceuticals. Approved paragraph IV ANDAs provide 180 …
Persistent link: https://www.econbiz.de/10012841381
Persistent link: https://www.econbiz.de/10001717519
Persistent link: https://www.econbiz.de/10001450321
driving the costs of pharmaceuticals, and develop a structured vector autoregressive (SVAR) model to measure the social rate …-run prices in pharmaceuticals themselves, but with lower long-run prices in the aggregate medical sector which includes … pharmaceuticals as a component part. Further, the TRIPS Agreement and Hatch-Waxman Act to enable generic competition have both been …
Persistent link: https://www.econbiz.de/10014209235